Demographic and Clinical Factors Associated with Patient-Reported Remission in Psoriatic Arthritis

[1] Singh JA(2019)Special article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis Arthritis Rheumatol Hoboken NJ 71 5-32

[2] Guyatt G(2010)Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment Ann Rheum Dis 69 48-53

[3] Ogdie A(2015)Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial Lancet Lond Engl 386 2489-2498

[4] Coates LC(2019)A novel role for the psoriatic arthritis impact of disease (PsAID) questionnaire Semin Arthritis Rheum 49 241-245

[5] Fransen J(2021)Is central sensitization an important determinant of functional disability in patients with chronic inflammatory arthritides? Ther Adv Musculoskelet Dis 13 1012-1019

[6] Helliwell PS(2014)A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative Ann Rheum Dis 73 835-842

[7] Coates LC(2010)Reliability, validity and responsiveness to change of the Patient Report of Extent of Psoriasis Involvement (PREPI) for measuring body surface area affected by psoriasis Br J Dermatol 162 343-347

[8] Moverley AR(2018)Validation of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire and its potential as a single-item outcome measure in clinical practice Ann Rheum Dis 77 49-285

[9] McParland L(2020)Validation and clinical interpretability of PsAID—psoriatic arthritis impact of disease Adv Rheumatol Lond Engl 60 279-436

[10] Johnson K(2017)The 12-item psoriatic arthritis impact of disease questionnaire: construct validity, reliability, and interpretability in a clinical setting J Rheumatol 44 423-1219

[1] Singh JA(2019)Special article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis Arthritis Rheumatol Hoboken NJ 71 5-32

[2] Guyatt G(2010)Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment Ann Rheum Dis 69 48-53

[3] Ogdie A(2015)Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial Lancet Lond Engl 386 2489-2498

[4] Coates LC(2019)A novel role for the psoriatic arthritis impact of disease (PsAID) questionnaire Semin Arthritis Rheum 49 241-245

[5] Fransen J(2021)Is central sensitization an important determinant of functional disability in patients with chronic inflammatory arthritides? Ther Adv Musculoskelet Dis 13 1012-1019

[6] Helliwell PS(2014)A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative Ann Rheum Dis 73 835-842

[7] Coates LC(2010)Reliability, validity and responsiveness to change of the Patient Report of Extent of Psoriasis Involvement (PREPI) for measuring body surface area affected by psoriasis Br J Dermatol 162 343-347

[8] Moverley AR(2018)Validation of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire and its potential as a single-item outcome measure in clinical practice Ann Rheum Dis 77 49-285

[9] McParland L(2020)Validation and clinical interpretability of PsAID—psoriatic arthritis impact of disease Adv Rheumatol Lond Engl 60 279-436

[10] Johnson K(2017)The 12-item psoriatic arthritis impact of disease questionnaire: construct validity, reliability, and interpretability in a clinical setting J Rheumatol 44 423-1219